US Military Cancer Institute Partners On Cancer Trial

Thu, 22 Feb 2007 05:00 AM EST

... The United States Military Cancer Institute (USMCI) and Generex Biotechnology Corporation announced that they have entered into a Phase II clinical trial for a novel peptide vaccine for breast cancer. The immunotherapeutic vaccine, AE37, is being developed by Generex's Antigen Express division in the U.S. The study will be conducted in conjunction with USMCI's Clinical Trials Group. [click link for full article] ...